江蘇荃信生物醫藥股份有限公司（02509）于2025年11月21日发布翌日披露报表，公告在香港联交所回购49,200股H股，占当日前已发行股份（不含库存股）约0.0217%。回购价格区间为每股19.96港元至20.60港元，合计支付约998,154.84港元。回购后公司已发行股份（不含库存股）数量变动至226,193,000股，库存股份增至878,600股。
公司已于2025年6月20日通过回购授权，授权总额为22,207,160股，截至目前合计回购878,600股。公司确认本次交易已遵守香港联交所上市规则及相关法律程序。公告由董事会秘书和联席公司秘书胡衍保签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.